Recent Eylea Growth Appears to be Coming from Expanded Uptake Among Prescribers Rather than from Initial Trial Among Late

     Recent Eylea Growth Appears to be Coming from Expanded Uptake Among
Prescribers Rather than from Initial Trial Among Late Adopters, According to a
                           Recent BioTrends Report

PR Newswire

EXTON, Penn., Jan. 7, 2013

EXTON, Penn., Jan. 7, 2013 /PRNewswire/ --BioTrends Research Group, one of
the world's leading research and advisory firms for specialized
biopharmaceutical issues, finds that, after one year on the market, 86 percent
of U.S. retinal specialists have prescribed Regeneron's Eylea to at least one
of their patients, a non-significant increase from six months post-launch (76
percent). Although Eylea prescriber base growth has been minimal, the mean
Eylea patient volume per prescriber has increased significantly compared to
previous waves, suggesting expanded uptake among Eylea prescribers. The
LaunchTrends^®: Eylea Wave 4  report also finds that retinal specialists
currently treat 15 percent of intravitreal-pharmaceutically-treated wet
age-related macular degeneration (AMD) patients with Eylea, representing a
significant increase compared to previous waves. Eylea-treated patients
continue to be largely switched to Eylea, either from Roche/Genentech's
Lucentis or Avastin, as opposed to being started on Eylea as their first-line
therapy, although significantly more retinal specialists now voice first-line
preference for Eylea compared to one month post-launch. It is important to
note, however, that Avastin continues to be preferred as a first-line
treatment option, largely due to its cost, while Eylea primarily competes with
Lucentis for second-line preference.

(Logo:http://photos.prnewswire.com/prnh/20130103/MM36805LOGO )

Similar to previous waves, Eylea's approved dosing frequency, which is
associated with less frequent injections and office visits, is reported
unaided as the biggest advantage of the agent compared to other treatment
options, and is considered the main driver for uptake among prescribers.
Retinal specialists continue to perceive Eylea's cost as its main disadvantage
and as the biggest obstacle to increased use, although they rate the managed
care approval process for Eylea as being significantly easier compared to one
and three months post-launch, and consider the agent to be performing
significantly better on managed care coverage.

Among the few retinal specialists who have never prescribed Eylea for wet AMD,
three-fifths expect to prescribe Eylea over the next six months, suggesting
that 94 percent of retinal specialists will have tried Eylea by 18 months
post-launch. In fact, retinal specialists anticipate Eylea share among wet AMD
patients to increase significantly to 26 percent over the next six months,
second only to Avastin at 54 percent. This clearly bodes well for continued
trial and uptake of the agent for wet AMD.

LaunchTrends^®: Eylea  is a four-wave syndicated report series designed to
track the uptake of Eylea at one month, three months, six months and one year
following its commercial availability based upon primary research with retinal
specialists. LaunchTrends assess trial and use of new products, obstacles to
use, reasons to use, typical patient types, line of therapy, product
perceptions, promotional efforts/messages and product satisfaction. In the
current wave of research, which measures Eylea's market impact at one year
post-launch, BioTrends surveyed 99 U.S. retinal specialists and conducted
qualitative interviews with a subset of 15 of the respondents in November
2012.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market
research to pharmaceutical manufacturers competing in clinically evolving,
specialty pharmaceutical markets. For information on BioTrends publications
and research capabilities, please contact us at (610) 321-9400 or
www.bio-trends.com. BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources Group
atwww.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be
trademarks of their respective holders.

For more information, contact:
BioTrends Research Group       Decision Resources Group
Emma Williams                  Christopher Comfort
610-321-9441                   781-993-2597
ewilliams@bio-trends.com       ccomfort@dresources.com

SOURCE BioTrends Research Group

Website: http://www.bio-trends.com
 
Press spacebar to pause and continue. Press esc to stop.